TABLE 3.
In vivo efficacy of WCK 771 by oral and s.c. administration for systemic MSSA infections caused by two strains of S. aureus
| Infecting strain and quinolone | MIC (μg/ml) | ED (mg/kg [95% confidence limit])a
|
|||
|---|---|---|---|---|---|
| s.c. route
|
Oral route
|
||||
| 50% | 90% | 50% | 90% | ||
| S. aureus ATCC 25923 | |||||
| WCK 771 | 0.03 | 0.59 (0.37-0.95) | 1.08 (0.67-1.71) | 2.8 (1.9-4.1) | 4.37 (3.0-6.3) |
| Moxifloxacin | 0.06 | 0.6 (0.3-1.2) | 1.7 (1.0-2.9) | 3.2* (1.9-5.2) | 9.6* (4.9-18) |
| Trovafloxacin | 0.015 | 0.26* (0.17-0.41) | 0.37 (0.2-0.5) | 1.0* (0.6-1.7) | 1.51* (0.9-2.4) |
| Sparfloxacin | 0.06 | 0.96* (0.66-1.39) | 1.7 (1.2-2.5) | 5.4* (4,3-6.3) | 7.0* (5.6-8.7) |
| S. aureus Smith (ATCC 13709) | |||||
| WCK 771 | 0.015 | 0.86 (0.5-1.3) | 2.4 (1.2-4.9) | 1.7 (0.93-0.06) | 5.0 (2.3-10.9) |
| Moxifloxacin | 0.06 | 1.0 (0.6-1.5) | 2.3 (1.3-4.2) | 3.2* (1.9-5.2) | 9.6* (4.9-18) |
| Trovafloxacin | 0.015 | 0.2* (0.04-0.9) | 0.9 (0.3-0.3) | 0.9* (0.6-1.4) | 2.18* (1.2-3.7) |
| Sparfloxacin | 0.06 | 0.6 (0.4-0.9) | 1.2 (0.7-2.1) | 3.85* (2.5-5.8) | 8.7* (5.1-14.9) |
a
ED50s and ED90s represent the means, and the 95% confidence limits are based on the results of three or four experiments. The results for ciprofloxacin, levofloxacin, moxifloxacin, and sparfloxacin were compared with those for WCK 771 by a one-way ANOVA, and results showing P values <0.05 are indicated with an asterisk.